LOSNING OCH SUBSTANS FOR DESS FRAMSTELLNING

A sterile aqueous solution containing 0.02 to 30 g per 100 ml solution of a mixture of isomalto-oligosaccharides comprising (a) 0-15 percent by weight of isomaltose, (b) 20-65 percent by weight of isomaltotriose, isomaltetraose and isomaltopentaose, each of these oligosaccharides being present in an amount of at least 5 percent by weight and at most 25 percent by weight, (c) 20-65 percent by weight of isomaltohexaose, isomaltoheptaose, isomaltooctaose and isomaltononaose, each of isomaltohexaose and isomaltoheptaose being present in an amount of at least 5 percent by weight and at most 25 percent by weight and the total amount of isomaltooctaose and isomaltononaose being at least 5 percent by weight and at most 25 percent by weight, 0-30 percent by weight of said mixture being isomaltooligosaccharides of 10 to 20 glucose units and 0-10 percent by weight of said mixture being isomaltooligosaccharides of 15 to 20 glucose units, the percentages being calculated on the total weight of the mixture of isomalto-oligosaccharides, and the use of said sterile aqueous solution for parenteral administration to mammals closely prior to or contemporaneously with the parenteral administration of clinical dextran to reduce the risks for adverse effects of the clinical dextran.